International journal of clinical and experimental pathology最新文献

{"title":"Biglycan promotes proliferation and metastasis of ovarian cancer.","authors":"Shan-Yu Fang, Xue-Mei Zhang, Xin-Ping Chen","doi":"10.62347/DOZK6884","DOIUrl":"https://doi.org/10.62347/DOZK6884","url":null,"abstract":"<p><strong>Objective: </strong>Ovarian cancer (OC) is a significant threat to the health of women. Biglycan (BGN) plays a crucial role in the oncogenesis and progression of various human cancers. The aim of this study was to clarify the role of BGN in OC.</p><p><strong>Methods: </strong>Immunohistochemical analysis was performed to detect BGN levels in the OC tissues of 68 patients who underwent cytoreductive surgery. Normal ovarian tissues were collected from 21 patients with benign gynecological tumors who underwent oophorectomy. Western blot analysis was conducted to detect BGN levels in human OC and normal ovarian cells. The functions of BGN in OC cells were assessed with the Cell Counting Kit-8, wound healing, and transwell migration assays following upregulation or downregulation of BGN <i>in vitro</i>.</p><p><strong>Results: </strong>BGN expression was elevated in OC tissues as compared to normal tissues. The basal level of BGN was also higher in OC cells than in normal cells. Knockdown of BGN reduced the proportion of surviving OC cells, increased wound healing, and decreased cell migration, while overexpression produced the opposite effects.</p><p><strong>Conclusions: </strong>These findings suggest that high BGN expression enhances proliferation and migration of OC cells, indicating that BGN is a potential target for treatment of OC.</p>","PeriodicalId":13943,"journal":{"name":"International journal of clinical and experimental pathology","volume":"18 4","pages":"166-172"},"PeriodicalIF":1.1,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12070128/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144077858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive model for prognosis, immune microenvironment and drug sensitivity of colon carcinoma based on cuproptosis-related genes.","authors":"Bo Zhao, Wenqi Lu, Yongjun Chen, Xiaoyong Cai","doi":"10.62347/FEEF1483","DOIUrl":"https://doi.org/10.62347/FEEF1483","url":null,"abstract":"<p><strong>Background: </strong>Colon cancer is a major cause of morbidity and mortality worldwide. Copper-induced cell death, known as cuproptosis, is a form of apoptosis that has been extensively studied in human diseases and is widely associated with tumor progression, prognosis, and immune response. However, the role of cuproptosis-related genes (CRGs) in the tumor microenvironment (TME) of colon cancer remains unclear.</p><p><strong>Objective: </strong>This study aims to explore the role of cuproptosis-related long non-coding RNAs (lncRNAs) in predicting the prognosis of colon cancer and to establish a risk prediction model based on these lncRNAs to guide clinical decisions and improve patient outcomes.</p><p><strong>Methods: </strong>A total of 19 cuproptosis-related genes were collected, and 1330 lncRNAs associated with cuproptosis were identified. Seven cuproptosis-related lncRNAs with prognostic value were selected from The Cancer Genome Atlas (TCGA) database. Using R software (version 4.1.0), the expression levels of the 19 genes were extracted, and the subjects were divided into high- and low-risk subgroups. A risk score model was developed based on cuproptosis-related genes and the seven co-expressed lncRNAs. The dataset was randomly split into a training set and a validation set. Analysis of clinicopathologic features, TME infiltration, and mutations was conducted, and nomogram predictions were validated using calibration plots to assess the predictive accuracy of the model.</p><p><strong>Results: </strong>The high-risk group had significantly shorter overall survival compared to the low-risk group (P<0.001), and the risk score was an independent prognostic factor (P<0.001). In the training set, the AUC values at 1, 3, and 5 years were 0.666, 0.621, and 0.669, respectively. Furthermore, low-risk patients had a higher survival rate. The genetic markers also correlated with tumor immune cell infiltration, clinical features, and prognosis.</p><p><strong>Conclusion: </strong>This study established a novel method based on cuproptosis-related lncRNAs to predict the prognosis of colon cancer. The model has potential clinical applications in identifying patients sensitive to immunotherapy and antitumor treatments, thereby enhancing precision treatment strategies for colon cancer.</p>","PeriodicalId":13943,"journal":{"name":"International journal of clinical and experimental pathology","volume":"18 4","pages":"148-165"},"PeriodicalIF":1.1,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12070126/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144077865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of naphthoquinone scaffold-derived compounds on head and neck squamous cell carcinoma based on network pharmacology and molecular docking.","authors":"Yiheng Liao, Lin Qiu, Anqi Tao, Cuiying Li","doi":"10.62347/CMQJ5473","DOIUrl":"https://doi.org/10.62347/CMQJ5473","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to analyze the effects of naphthoquinone scaffold-derived compounds on head and neck squamous cell carcinoma (HNSCC) using network pharmacology and molecular docking.</p><p><strong>Methods: </strong>We screened candidate compounds from the ASINEX database and evaluated their drug likeness and toxicity. They identified 80 compounds with naphthalenone structures, focusing on 1,4-naphthoquinone and 1,2-naphthoquinone scaffolds. The possible targets of these compounds were predicted using databases like SwissTargetPrediction and Similarity Ensemble Approach Database (SEA).</p><p><strong>Results: </strong>The common targets between the compounds and HNSCC were identified, yielding 65 overlapping targets. A protein-protein interaction (PPI) network was constructed, and 20 hub genes were identified based on centrality metrics. Gene ontology (GO) enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis revealed that these compounds' protective effects against HNSCC are associated with cancer-related pathways, such as those in cancer and proteoglycans in cancer. Molecular docking was performed to evaluate the binding affinity between the compounds and hub genes. The results showed that the compounds had strong binding affinities with key targets like MET and TYK2, with binding energies < -5 kcal/mol.</p><p><strong>Conclusions: </strong>The study suggests that naphthoquinone derivatives could serve as novel chemotherapy agents for HNSCC, warranting further research for clinical application.</p>","PeriodicalId":13943,"journal":{"name":"International journal of clinical and experimental pathology","volume":"18 4","pages":"130-147"},"PeriodicalIF":1.1,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12070129/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144077860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intraductal papillary mucinous neoplasm of the intrahepatic bile duct: a case report and literature review.","authors":"Ying Zhang, Fan Jia, Kai-Ge Wang","doi":"10.62347/NZTK3263","DOIUrl":"https://doi.org/10.62347/NZTK3263","url":null,"abstract":"<p><p>Intraductal papillary mucinous neoplasm of the bile duct (IPMN-B) is a rare malignant tumor originating from the bile duct epithelium, characterized by its ability to secrete large amounts of mucin, which can lead to biliary obstruction. This paper presents a case involving a 69-year-old woman presenting with intermittent right upper abdominal pain, imaging revealed dilation of the left intrahepatic bile duct and the presence of a solid mass. We performed left lateral hepatectomy on the patient, and the postoperative pathological diagnosis was intraductal papillary tumor with associated invasive carcinoma. At the 6-month postoperative follow-up, the patient showed no signs of recurrence and was in good condition. This case underscores the high malignant potential of IPMN-B, emphasizing the importance of early surgical resection following diagnosis to achieve a favorable prognosis and improve patient outcomes.</p>","PeriodicalId":13943,"journal":{"name":"International journal of clinical and experimental pathology","volume":"18 4","pages":"173-178"},"PeriodicalIF":1.1,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12070127/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144077862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of the efficacy and safety of toripalimab combination therapy for treatment of advanced gastric cancer: a meta-analysis.","authors":"Xinlin Yu, Ran Cui, Ping Guo","doi":"10.62347/GZOW5960","DOIUrl":"https://doi.org/10.62347/GZOW5960","url":null,"abstract":"<p><strong>Background: </strong>To systematically evaluate the efficacy and safety of combination therapy with toripalimab in the treatment of advanced gastric cancer (GC).</p><p><strong>Methods: </strong>We conducted a thorough search for relevant studies in PubMed, Embase, Cochrane Library, and Web of Science. Effect estimates were computed utilizing Stata software (version 14.0) and either random or fixed effects models, as applicable. A subgroup analysis was undertaken to assess the effect of various combination therapies on overall response rate (ORR). Begg and Egger's tests were employed to assess publication bias.</p><p><strong>Results: </strong>The study consisted of 8 trials, which included 277 participants with advanced gastric cancer. The overall ORR was 41.4% (95% CI, 32.4%-50.3%), with a disease control rate (DCR) of 83.6% (95% CI, 74.6%-92.7%), a median overall survival (mOS) of 11.0 months (95% CI, 9.6-12.4), and a median progression-free survival (mPFS) of 4.2 months (95% CI, 2.5-6.0) for the combination therapy with toripalimab. Subgroup analysis revealed that the combination of toripalimab and chemotherapy achieved a greater ORR compared to the non-chemotherapy group, with ORR rates of 49.8% (95% CI, 42.2%-57.4%) and 31.9% (95% CI, 26.7%-37.1%), respectively. The combination therapy with toripalimab led to adverse events (AEs) of any grade at 94.0% of cases (95% CI, 89.5%-98.5%) and grade 3 AEs at 32.4% (95% CI, 17.8%-47.1%). The sensitivity analysis indicated that no single study affected the overall results.</p><p><strong>Conclusions: </strong>Combination therapy of toripalimab can improve clinical efficacy, although with increased but manageable toxicity. Additional clinical trials are required to assess comprehensively the efficacy and safety of alternative toripalimab regimens. The review agreement has been recorded with PROSPERO (CRD42024585696).</p>","PeriodicalId":13943,"journal":{"name":"International journal of clinical and experimental pathology","volume":"18 3","pages":"96-109"},"PeriodicalIF":1.1,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11982770/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143993361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of a glycolysis-associated lncRNA signature to predict survival of patients with colorectal cancer.","authors":"Gaoceng Zhu, Yutian Kang, Mei Luo, Linling Ju, Yajun Sun, Lin Chen","doi":"10.62347/RVLY4737","DOIUrl":"https://doi.org/10.62347/RVLY4737","url":null,"abstract":"<p><strong>Objective: </strong>Colorectal cancer (CRC) still has a poor prognosis and is one of the most common malignancies worldwide. Recently, a close correlation between glycolysis and the progression of CRC has been reported. Hence, explorations of the prognostic value of glycolysis-associated long noncoding RNAs in CRC patients are urgently needed. This study aimed to investigate the role of glycolysis-associated lncRNAs for predicting the prognosis and treatment response of CRC, thereby identifying more biomarkers for CRC.</p><p><strong>Methods: </strong>RNA sequencing (RNA-seq) data for CRC from The Cancer Genome Atlas database were used. A glycolysis-associated long noncoding RNA (lncRNA) signature was estimated by Cox regression analysis, and its predictive capacity was assessed by constructing a receiver operating characteristic (ROC) curve and performing a gene set enrichment analysis.</p><p><strong>Results: </strong>One of our constructed glycolysis-related clusters was strongly correlated with an immunosuppressive tumor environment. Moreover, a signature consisting of 14 glycolysis-associated lncRNAs was used as a prognostic model, and CRC patients were classified into a low-risk group and a high-risk group based on the average risk score of this signature. In addition, the low-risk group experienced longer overall survival (OS) than the high-risk group. The area under the ROC curve (AUC) validated the sensitivity and specificity of the signature. The signature was identified as an individual element and was closely related to the progression of CRC. Finally, two glycolysis-associated lncRNAs, namely, TNFRSF10A-AS1 and ZKSCAN2-DT, were further clinically verified to effectively predict the prognosis of CRC patients.</p><p><strong>Conclusion: </strong>Glycolysis-associated lncRNAs may be employed as prognostic and therapeutic biomarkers for CRC.</p>","PeriodicalId":13943,"journal":{"name":"International journal of clinical and experimental pathology","volume":"18 3","pages":"110-122"},"PeriodicalIF":1.1,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11982773/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144010515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum: NKD1 down-regulation is associated with poor prognosis in breast invasive ductal carcinoma.","authors":"Zhi-Dong Lv, Lin Zhang, Xiang-Ping Liu, Li-Ying Jin, Qian Dong, Fu-Nian Li, Hai-Bo Wang, Bin Kong","doi":"10.62347/BKQJ1119","DOIUrl":"https://doi.org/10.62347/BKQJ1119","url":null,"abstract":"<p><p>[This corrects the article on p. 4015 in vol. 8, PMID: 26097589.].</p>","PeriodicalId":13943,"journal":{"name":"International journal of clinical and experimental pathology","volume":"18 3","pages":"128-129"},"PeriodicalIF":1.1,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11982771/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143994395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Collision tumor of low grade endometrial stromal sarcoma and cervical squamous cell carcinoma: a case report.","authors":"Xuxuan Zhang, Xiao Tang","doi":"10.62347/FWIW8283","DOIUrl":"https://doi.org/10.62347/FWIW8283","url":null,"abstract":"<p><p>Uterine collision tumor is a rare pathologic type composed of two or more malignant tumors, with cervical collision tumors being even rarer. The mechanism of occurrence of collision tumors is not clear. We hope to help clinicians and pathologists understand and diagnose this condition. We report a case of a 53-year-old female diagnosed with poorly differentiated squamous cell carcinoma of the cervix through biopsy. After reviewing previous reports on collision tumors in different locations and theiry types in the cervix and uterus, we found that collisions between cervical squamous cell carcinoma and low-grade endometrial stromal sarcoma were rare. Identifying this type of collision tumor may help with future diagnosis and treatment.</p>","PeriodicalId":13943,"journal":{"name":"International journal of clinical and experimental pathology","volume":"18 3","pages":"123-127"},"PeriodicalIF":1.1,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11982772/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143964423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sequencing of high-frequency mutated genes in breast cancer (BRCA) and associated-functions analysis.","authors":"Xuelian Li, Mei Yang, Liyuan Yang, Xuefei Dang, Xueqing Li, Gang Li","doi":"10.62347/YODE5431","DOIUrl":"10.62347/YODE5431","url":null,"abstract":"<p><strong>Objective: </strong>Mutations or aberrant expression of genes in an organism tend not to be completely random and this cumulative effect predisposes to the development of malignant tumours. This study aims to reveal the possible aberrant expression of high frequency mutated genes, and then to investigate their role in development, prognosis, signalling pathway function and drug resistance in breast cancer.</p><p><strong>Methods: </strong>The mutated genes in breast cancer (BRCA) clinical samples were identified and detected by high-throughput sequencing. High-frequency mutant genes were counted. Gene expression profiles and the relationship with prognosis were analysed throughout TCGA database. qRT-PCR was used to analyse the mRNA levels of the six high-frequency mutant genes in BRCA tissues and cell lines. IHC was used to analyse the protein levels of the six high-frequency mutant genes in BRCA tissues. The linear interaction, single-cell layer clustering status and the influence in immune cell infiltration degree among these six high-frequency mutant genes were analysed by bioinformatics analysis. The STITCH and cMAP datasets were used for high-frequency mutant gene interaction networks, association signalling pathway enrichment and drug-transcriptome analyses. The effects of trastuzumab on the proliferative capacity of breast cancer cells, as well as on the expression of six high-frequency mutated genes were determined by CCK8 assay.</p><p><strong>Results: </strong>The genes that were statistically found to have high-frequency mutations in the samples recruited in the present study by high-throughput sequencing analysis included TP53, PIK3CA, NF1, TBX3, BRCA1 and BRCA2. The expression profiles of these genes and the correlation with prognosis were further demonstrated using the TCGA database: the trend in this study was similar to that of BRCA in TCGA. The mRNA and protein expression of these genes showed that the expression of TP53, NF1, TBX3, BRCA1 and BRCA2 was higher in tumor samples than that in normal samples, with an opposite trend for PIK3CA, a similar trend was observed in BRCA cell lines. The protein expressions of TP53, NF1, TBX3, BRCA1 and BRCA2 displayed the same trend by IHC. Other correlation results include 1) the single cell layer clustering of these six genes resulted in significant clustering with few overlapping regions; 2) these six genes showed different degrees of influence on BRCA immune cell infiltration; 3) these six genes showed a significant correlation between each other; 4) the network of each gene had partially overlapping molecules; and 5) the PI3K pathway was a key association pathway in BRCA. Finally, the cell proliferation ability results confirmed the optimal concentration of trastuzumab and its effect on mRNA expression of these six genes.</p>","PeriodicalId":13943,"journal":{"name":"International journal of clinical and experimental pathology","volume":"18 2","pages":"46-62"},"PeriodicalIF":1.1,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11897711/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143624538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Non-invasive low-grade papillary urothelial carcinoma with whorled features: a report of two cases.","authors":"Kiran Madwani, Pramila Moideen, Michael P Toscano, Lakshmi K Vemavarapu, Trent D Trzpuc, Suash J Sharma","doi":"10.62347/DFQO7724","DOIUrl":"10.62347/DFQO7724","url":null,"abstract":"<p><p>Non-invasive papillary urothelial carcinomas present as cytoarchitectural disorders without invasion through the basement membrane. They are divided into low-grade and high-grade categories on the basis of the extent of cytologic atypia and architectural disarray. Notably, divergent differentiation (such as squamous and glandular differentiation) and variants (such as nested, micropapillary, plasmacytoid, and sarcomatoid) are reported primarily in invasive and high-grade urothelial carcinomas. We present two cases of low-grade non-invasive papillary urothelial carcinoma with recently described whorled features (urothelial eddies). Both patients were 77-year-old males with small papillary lesions in the bladder. Histopathologic examination revealed low-grade non-invasive papillary urothelial carcinoma with a sporadic whorled pattern. Patient number 1's tumor exhibited cytokeratin (CK) 20 immunopositivity, up to 5% Ki-67 labeling, and wild-type p53 staining. Patient number 2's tumor was negative for CK20 with wild type p53 staining in portions with whorls, but demonstrated diffuse CK20 and extensive p53 staining (possible mutation) in tumor portions lacking whorls. Patient number 1 experienced a 14-month recurrence and a second possible recurrence 43 months after the initial diagnosis. Patient number 2 experienced recurrence of low-grade papillary urothelial carcinoma with focal whorls in one location and subsequently a distinct low-grade papillary urothelial carcinoma with whorled features in a different part of the bladder. Our limited study supports the reported association of rare whorled features with non-invasive low-grade papillary urothelial carcinoma, albeit with a diverse immunophenotype. Evaluation of both whorled and non-whorled areas in the histology along with CK20 and p53 staining may be helpful for complete diagnostic and prognostic evaluation of these cases.</p>","PeriodicalId":13943,"journal":{"name":"International journal of clinical and experimental pathology","volume":"18 2","pages":"89-95"},"PeriodicalIF":1.1,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11897714/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143624534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}